Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Bio Drugs to Account for 30% of All Drugs in 2010: Mr Nagayama at Medical Forum
November 4, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 4, 2002
-
ARCHIVE Kuraya Sanseido to Achieve 2% Operating Profit Rate by Further Cutting Costs
November 4, 2002
-
ARCHIVE Takeda Develops Simulation Software to Predict Prognosis of Diabetic Complications
November 4, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
October 28, 2002
-
ARCHIVE Matsumotokiyoshi Ties Up with Koyo Yakuhin
October 28, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
October 28, 2002
-
ARCHIVE Interim Report Drafted on Promotion of OTC Drugs
October 28, 2002
-
ARCHIVE Korosho to Take Measures to Improve Quality of Medical Services
October 28, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 28, 2002
-
ARCHIVE Review Fees to Be Hiked in April 2004
October 28, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
October 28, 2002
-
ARCHIVE Council Recommends Strategic Approaches toward IP
October 28, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
October 28, 2002
-
ARCHIVE 3 Active Ingredients Including Flunase Nasal Solution Approved
October 28, 2002
-
ARCHIVE Sankyo Acquires Cider Sante's Subsidiary of France
October 28, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF -1-
October 28, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF -2-
October 28, 2002
-
ARCHIVE WMA General Assembly Washington 2002
October 28, 2002
-
ARCHIVE Profit-Making Companies to Not Be Allowed to Operate Medical Facilities
October 28, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…